ClinicalTrials.gg
CompletedNCT01288001Updated Nov 21, 2012

Study of Evaluating the Duration of Efficacy of One Intra Articular Injection of Sodium Hyaluronate 2.0% in Patients With Painful Osteoarthritis of the Knee

A Phase 2 interventional study of Ostenil plus in Osteoarthritis Patient, sponsored by TRB Chemedica. Completed at 1 site in Thailand. Open to participants aged 40 Years to 70 Years. Per ClinicalTrials.gov, last updated 2012-11-21.

Sponsored by TRB Chemedica · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
40 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 24 studies in Osteoarthritis with a site in Thailand — 2 open to participants now, 2 under way, none of them phase 3. Osteoarthritis · Thailand.

Enrollment
20th of 20
20 · median 87
Started
2011
with 1 other
Phase 2
2 of 24
none open now
Registered
9th of 24
by date

Among the 24 studies in Osteoarthritis with a site in Thailand, this one is the 20th largest by enrollment of the 20 interventional ones that give a count, is one of 2 that started in 2011, is one of 2 in phase 2, and was the 9th registered.

Osteoarthritis

2,978 studies on the registry are indexed under Osteoarthritis; 438 are open to participants now.

Browse Osteoarthritis studies →

Open to participants now

2 of the 24 studies in Osteoarthritis with a site in Thailand are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →

Who these studies take

Of the 285 Osteoarthritis studies recruiting now, 158 (55%) set no upper age limit and 70 (25%) stop at 75 or younger; 22 take children under 18; 31 take healthy volunteers.

This study: 40 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 24 studies in Osteoarthritis with a site in Thailand, or all of them as a file.
02

Study summary

A pilot, open, randomised, controlled, add-on study evaluating the duration of efficacy of one intra articular injection of sodium hyaluronate 2.0% in patients with painful osteoarthritis of the knee

03

Conditions studied

  • Osteoarthritis Patient

Browse trials for

04

Who can participate

Ages eligible
40 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of both genders between 40 and 70 years of age;
  2. Primary tibiofemoral osteoarthritis of the knee according to American College of Rheumatology criteria;
  3. Pain ≥ 4 on a 10 point scale for at least two out of five subscores of the WOMAC Section A at baseline;
  4. Radiologically ascertained grade II or III severity knee osteoarthritis on the Kellgren-Lawrence scale;
  5. Having given signed .

Exclusion criteria

Exclusion Criteria:

  1. Secondary knee osteoarthritis, including:

    • septic arthritis;
    • inflammatory joint disease;
    • gout;
    • recurrent episodes of pseudogout;
    • Paget's disease of bone;
    • articular fracture;
    • ochronosis;
    • acromegaly;
    • haemochromatosis;
    • Wilson's disease;
    • primary osteochondromatosis.
  2. Clinical signs of acute flare (pain, warm, erythema, effusion of signal knee) at baseline;
  3. Axial deviation > 15 degrees in valgus or varus on a standing X-ray;
  4. medio-lateral or antero-posterior instability;
  5. Rapid destructive arthritis, evolving arthritis requiring surgery within the coming year;
  6. Significant injury to the signal knee within 6 months prior to baseline;
  7. Complete loss of range of motion;
  8. Painful knee conditions other than osteoarthritis (e.g., Sudeck's atrophy, intra-articular neoplasm, villonodular synovitis);
  9. Necrosis of one of the femur condyles;
  10. History or evidence of gout, chondrocalcinosis;
  11. Peripheral neuropathy;
  12. Concomitant rheumatic disease:

    • fibromyalgia;
    • rheumatoid arthritis;
    • collagen diseases;
    • psoriatic arthritis and other seronegative spondylarthropathies (e.g., ankylosing spondylitis);
    • metabolic and crystal-induced arthropathies;
    • other osteopathies.
  13. to intra-articular injection according to investigator's judgement (e.g., local infection at injection site, generalised infection with possible bacteraemia);
  14. Skin disease in the area of injection;
  15. Severe coagulopathy, ongoing anticoagulation therapy;
  16. Accompanying OA of the hip of sufficient severity to interfere with the assessment of the signal knee;
  17. Disease of spine, hip or other lower extremity joints of sufficient degree to affect assessment of the signal knee;
  18. Poor general health interfering with compliance or assessment;
  19. Concomitant disease/ailment other than knee OA requiring the regular use of the patient's normal analgesic medicine;
  20. Initiation of chronic treatment with antihistaminics, , antidepressants or tranquilisers, within less than 3 months prior to baseline;
  21. Use of assistive devices other than a cane (walking stick);
  22. Surgery of the signal knee other than arthroscopy;
  23. Arthroscopy of the signal knee within one year prior to baseline;
  24. Treatment with symptomatic slow acting drug for OA (SYSADOA, i.e., chondroitin sulfate, diacerein, glucosamine, piascledine), unless the patient has been on a stable dose for at least 4 months prior to baseline;
  25. Intra-articular depocorticosteroid injection into the signal knee within 3 months prior to baseline;
  26. Intra-articular SH injection into the signal knee within 6 months prior to baseline;
  27. Ascertained to any product used in the study (SH, paracetamol, diclofenac, omeprazole) or to similar compounds;
  28. Pregnant or lactating female;
  29. Female of without adequate methods;
  30. Participation in a drug clinical trial within 3 months prior screening;
  31. Patients who, in the judgement of the investigator, will not comply with the protocol.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Ostenil plus

    Patient will get Ostenil plus injection and standard treatment of Osteoarthritis

    Drug: Ostenil plus

Interventions

  • DrugOstenil plus

    2% Sodium Hyaluronate plus Mannitol injection

06

What researchers measure

Primary outcomes

  1. to evaluate the duration of efficacy of one intra articular injection of Ostenil® Plus in patients with painful osteoarthritis of the knee.

    WOMAC score

    Time frame: 6 months

Secondary outcomes

  1. to evaluate the effects of the study treatment on pain, joint stiffness, joint function and need for analgesic consumption.

    Time frame: 6 months

07

Study locations

1 site
  • Siriraj Hospital
    Bangkoknoi, Bangkok 10700, Thailand
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2011, a primary completion of Dec 2011 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2011
First posted
Feb 2, 2011
Start
Mar 2011
Primary completionActual
Dec 2011
CompletionActual
Jul 2012
Last update
Nov 21, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 21, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01288001
Lead sponsor
TRB Chemedica
Responsible party
Sponsor
First posted
Feb 2, 2011
Start date
Mar 2011
Primary completion
Dec 2011
Completion
Jul 2012
Last update
Nov 21, 2012
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion